N-[4-(dimethylamino)phenyl]-N-[4-(4-pyridyl)-1,3-thiazol-2-yl]amine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-[4-(dimethylamino)phenyl]-N-[4-(4-pyridyl)-1,3-thiazol-2-yl]amine
• 英文别名: 4-N,4-N-dimethyl-1-N-(4-pyridin-4-yl-1,3-thiazol-2-yl)benzene-1,4-diamine
• 化学式: C₁₆H₁₆N₄S
• 分子量: 296.4
• InChiKey: GYKBWMROJGRQQE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Compounds and Uses Thereof in Modulating Amyloid Beta
  申请人：Cheng Soan

  公开号：US20070260058A1

  公开（公告）日：2007-11-08

  Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.

  本发明提供了新的化合物、组合物和试剂盒。还提供了调节Aβ水平的方法以及治疗与异常Aβ水平相关的疾病的方法。
• COMPOSITIONS AND METHODS RELATING TO HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATING COMPOUNDS AND TARGETS THEREOF
  申请人：Thiele Dennis J.

  公开号：US20130267543A1

  公开（公告）日：2013-10-10

  The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

  本发明涉及HSF激活化合物、其发现方法以及它们的研究和治疗用途，以及药学上可接受的盐、溶剂化合物、螯合物、非共价复合物、前药、混合物（包括R和S对映体形式和它们的混合物）和其制剂。具体而言，本发明提供了能够促进HSF1同源三聚体形成的化合物，并使用这些化合物作为治疗剂治疗与不规则HSF1活性有关的多种疾病。
• SUBSTITUTED PYRAZOLES AS HEAT SHOCK TRANSCRIPTION FACTOR ACTIVATORS
  申请人：DUKE UNIVERSITY

  公开号：US20160221958A1

  公开（公告）日：2016-08-04

  The present invention relates to HSF activating compounds, methods for their discovery, and their research and therapeutic uses, as well as pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, mixtures (including both R and S enantiomeric forms and racemic mixtures thereof), and pharmaceutical Formulations thereof. In particular, the present invention provides compounds capable of facilitating HSF1 homotrimerization, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with irregular HSF1 activity.

  本发明涉及HSF激活化合物，其发现方法以及它们的研究和治疗用途，以及其药学上可接受的盐，溶剂化物，螯合物，非共价复合物，前药，混合物（包括R和S对映体形式和它们的混合物），以及其制剂。特别是，本发明提供了能够促进HSF1同源三聚体形成的化合物，以及使用这些化合物作为治疗剂治疗与不规则HSF1活性相关的多种疾病的方法。
• COMPOUNDS AND USES THEREOF IN MODULATING AMYLOID BETA
  申请人：Cheng Soan

  公开号：US20100324032A1

  公开（公告）日：2010-12-23

  Novel compounds, compositions, and kits are provided. Methods of modulating Aβ levels, and methods of treating a disease associated with aberrant Aβ levels are also provided.

  本发明提供了新型化合物、组合物和试剂盒。还提供了调节Aβ水平的方法和治疗与异常Aβ水平相关的疾病的方法。
• US7244739B2
  申请人：——

  公开号：US7244739B2

  公开（公告）日：2007-07-17